Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer by Miso Kim et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Kim et al. World Journal of Surgical Oncology 2014, 12:37
http://www.wjso.com/content/12/1/37RESEARCH Open AccessPreoperative thrombocytosis is a significant
unfavorable prognostic factor for patients with
resectable non-small cell lung cancer
Miso Kim1†, Hyun Chang1†, Hee Chul Yang2, Yu Jung Kim1, Choon-Taek Lee1, Jae-Ho Lee1, Sanghoon Jheon2,
Kwhanmien Kim2, Jin-Haeng Chung3 and Jong Seok Lee1,4*Abstract
Background: Previous studies have reported that pretreatment thrombocytosis is associated with poor outcomes
in several cancer types. This study was designed to evaluate the prognostic significance of preoperative
thrombocytosis in patients with non-small cell lung cancer (NSCLC) who undergo surgery.
Methods: We retrospectively reviewed the records of 199 patients who underwent R0 resection for NSCLC
between May 2003 and July 2006 at Seoul National University Bundang Hospital, Seongnam, Korea.
Results: The frequency of preoperative thrombocytosis was 7.5% (15/199). Patients with preoperative
thrombocytosis had shorter overall survival (OS, P = 0.003) and disease-free survival (DFS, P = 0.005) than those
without thrombocytosis. In multivariable analysis, patients with preoperative thrombocytosis had a significantly
greater risk of death and recurrence than those without preoperative thrombocytosis (risk of death: hazard ratio
(HR) 2.98, 95% confidence interval (CI) 1.39 to 6.37, P = 0.005; risk of recurrence: HR 2.47, 95% CI 1.22 to 5.01,
P = 0.012). A tendency towards a shorter OS and DFS was observed in three patients with persistent thrombocytosis
during the follow-up period when compared with those of patients who recovered from thrombocytosis after
surgery.
Conclusions: Preoperative thrombocytosis was valuable for predicting the prognosis of patients with NSCLC.
Special attention should be paid to patients with preoperative and postoperative thrombocytosis.
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Lung cancer is the most common cause of cancer-
related death worldwide [1]. Non-small cell lung cancer
(NSCLC) accounts for approximately 80% of all lung
cancers. There are several known prognostic factors for
patients with NSCLC. The most important prognostic
factor for NSCLC is tumor stage, with advanced stage
disease being associated with the poorest prognosis. Sev-
eral studies have shown the relationship of pretreatment* Correspondence: jslee@snubh.org
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reproduction in any medium, provided the orhematologic abnormalities such as anemia, leukocytosis,
or thrombocytosis with adverse outcomes in patients
with lung cancer [2-7]. In particular, tumor-related throm-
bocytosis is frequently observed in patients with advanced
stages of various malignancies and many experimental
and clinical studies have been performed to explain this
phenomenon. However, the mechanism of thrombocytosis
in patients with cancer is not yet fully understood. It re-
mains unclear whether thrombocytosis is the final result
of advanced malignancies or the direct cause that in-
creases the risk of recurrence and metastasis. This study
was designed to evaluate the prognostic value of preopera-
tive thrombocytosis in patients with NSCLC who undergo
surgery.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 The relationship between preoperative







≤64 90 (92.8) 7 (7.2)
>65 94 (92.2) 8 (7.8)
Gender 0.765
Male 137 (91.9) 12 (8.1)
Female 47 (94) 3 (6)
Smoking history 0.003
No 63 (100.0) 0 (0)
Yes 121 (89.0) 15 (11.0)
Histology 0.002
ADC 104 (97.2) 3 (2.8)
SCC 63 (84.0) 12 (16.0)
Others 17 (100.0) 0 (0)
Leukocytosis 0.004
(−) 173 (94.0) 11 (6.0)
(+) 11 (73.3) 4 (26.7)
Anemia <0.001
(−) 145 (96.6) 5 (3.4)
(+) 39 (79.5) 10 (20.5)
Stage 0.432
I 93 (93.9) 6 (6.1)
II to III 91 (91.0) 9 (9.0)
pT 1.000
1 34 (94.4) 2 (5.6)
2 to 4 150 (92.0) 13 (8.0)
pN 0.687
0 113 (91.9) 10 (8.1)
1 to 3 71 (93.4) 5 (6.6)
ADC, adenocarcinoma; SCC, squamous cell carcinoma.
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Patients
The medical records of 274 consecutive patients who
underwent surgical resection (lobectomy or pneumonec-
tomy) of NSCLC between May 2003 and July 2006 at
Seoul National University Bundang Hospital, Seongnam,
Korea, were reviewed. Subsequently, 75 patients were
excluded from the study because of the following ex-
clusion criteria: 1) synchronous extrapulmonary malig-
nancy; 2) apparent acute inflammatory disease in which
the platelet count can rise; and 3) severe liver cirrhosis
that may cause the platelet count to decline. The remai-
ning 199 patients who underwent complete resection,
either lobectomy or pneumonectomy with mediastinal
lymph node sampling, were enrolled in the study. Data
on patient demographics, laboratory results, and path-
ology based on the seventh edition of the American Joint
Committee on Cancer staging system were evaluated.
The study protocol was reviewed and approved by the
Institutional Review Board of the Seoul National Uni-
versity Bundang Hospital. The study was conducted in
accordance with the principles of the Declaration of
Helsinki.
Definition
Preoperative white blood cell count, hemoglobin level,
and platelet count before invasive diagnostic procedures
and within 4 weeks before surgery were determined.
Leukocytosis was defined as a white blood cell count of
more than 1.0 × 104/mm3. A hemoglobin level of less
than 13.0 g/dL in men and less than 12.0 g/dL in women
was considered as anemia. A platelet count of more than
40 × 104/μL was defined as thrombocytosis, in agreement
with other studies.
Statistical analysis
Overall survival (OS) and disease-free survival (DFS) were
defined as the time elapsed between the date of surgery
and the date of death and the date of recurrence, res-
pectively. Significant differences in variables in relation
to thrombocytosis were tested using chi-square test or
Fisher’s exact test, as appropriate. OS and DFS were evalu-
ated using Kaplan–Meier analysis, and comparisons of
survival between the two groups were made using the log-
rank test.
The relative impact of variables was analyzed by uni-
variate analysis using the Cox proportional hazards re-
gression method. Multivariate analysis was performed
using a backward stepwise method. pT and pN stage
were excluded from multivariate analysis due to multi-
collinearity. Variables with clinical significance and stat-
istical significance levels of less than 0.05 were selected
for covariate analysis. Variables with a P value of more
than 0.10 were removed during stepwise analysis. Two-tailed P values of less than 0.05 were considered statisti-
cally significant. All analyses were performed using IBM




Patient clinicopathological characteristics are summa-
rized in Table 1. The study population was predomin-
antly male (74.9%), with a median age of 65 years (range:
20 to 84 years). Among 199 patients, there were 136
(68.3%) current or past smokers. Adenocarcinoma was
the most frequent histologic type (53.8%). Overall, 99
patients had stage I cancer, whereas 100 patients had
stage II or III tumors. Seventeen patients received neo-
adjuvant chemotherapy. Adjuvant chemotherapy with or
Figure 1 Correlation between preoperative thrombocytosis and
overall survival. Kaplan–Meier plots of overall survival of patients
with resectable NSCLC according to preoperative thrombocytosis
(P = 0.003). NSCLC, non-small cell lung cancer.
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gical resection. The frequency of preoperative thrombo-
cytosis was 7.5% (15/199).
The relationship between preoperative thrombocytosis
and clinicopathological factors is shown in Table 1. Preo-
perative thrombocytosis did not show a correlation with
age, gender, or tumor stage. Smoking history and histo-
logical types were associated with preoperative thrombo-
cytosis (P = 0.003 and P = 0.002, respectively).Table 2 Univariate and multivariate analysis of prognostic fac
Variable Category Univa
HR (95% CI)
Age (years) >65/≤64 2.99 (1.69 to 5.34)
Gender Female/Male 1.56 (0.81 to 3.00)
Smoking Yes/No 2.03 (1.07 to 3.83)
Histology Others/ADC 1.59 (0.94 to 2.68)
Stage II + III/I 1.76 (1.03 to 3.01)
pT 2 to 4/1 2.38 (1.02 to 5.59)
pN 1 to 3/0 1.44 (0.86 to 2.43)
Leukocytosis Yes/No 1.34 (0.54 to 3.36)
Anemia Yes/No 1.68 (0.97 to 2.91)
Thrombocytosis Yes/No 2.93 (1.38 to 6.22)
ADC, adenocarcinoma; CI, confidence interval; HR, hazard ratio.Survival analysis
With a median follow-up period of 65 months (range:
0.7 to 102 months), the 5-year OS and DFS rates were
75.2% and 58.3%, respectively. The 5-year OS rate of pa-
tients with thrombocytosis was significantly lower than
that of patients without thrombocytosis (45.0% versus
75.2%, P = 0.003; Figure 1). Univariate analysis identi-
fied age (P <0.001), smoking history (P = 0.030), stage
(P = 0.037), and preoperative thrombocytosis (P = 0.005)
as significant prognostic factors for OS. Multivariate ana-
lysis confirmed that age (P <0.001), stage (P = 0.034), and
preoperative thrombocytosis (P = 0.005) were independent
poor prognostic factors for OS (Table 2).
With a median DFS of 50 months for all patients,
the 5-year DFS rate of patients with thrombocytosis
was significantly lower than that of patients without
thrombocytosis (38.1% versus 68.1%, P = 0.005; Figure 2).
Eighty-one patients (40.7% of all patients) developed
recurrence. Nine (60%) of the 15 patients with throm-
bocytosis showed recurrence, whereas 73 (40%) of the
184 patients without thrombocytosis showed recurrence.
Univariate analysis showed that age, stage, pT, pN, pre-
operative anemia, and preoperative thrombocytosis were
significant prognostic factors for recurrence. Multivariate
analyses confirmed that age (P = 0.046), stage (P <0.001),
and preoperative thrombocytosis (P = 0.012) were inde-
pendent prognostic determinants of recurrence (Table 3).
Platelet counts were normalized in 12 out of 15 pa-
tients with preoperative thrombocytosis. Among these
12 patients, seven patients recovered from thrombocy-
tosis within 1 month and five patients recovered from
thrombocytosis after a few months (median, 1.2 months).
Thrombocytosis persisted during the follow-up period in
three out of 15 patients. Of these three patients with
persistent thrombocytosis, two patients developed sys-
temic recurrence and one had a local relapse after sur-
gery. A tendency towards a shorter OS and DFS wastors for overall survival
riate Multivariate
P value HR (95% CI) P value









0.005 2.98 (1.39 to 6.37) 0.005
Figure 2 Correlation between preoperative thrombocytosis and
disease-free survival. Kaplan–Meier plots of disease-free survival
of patients with resectable NSCLC according to preoperative
thrombocytosis (P = 0.005). NSCLC, non-small cell lung cancer.
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bocytosis when compared with those of patients who re-
covered from thrombocytosis (median OS, 63 months
versus 15 months, P = 0.064; median DFS, 15 months
versus 6 months, P = 0.142).
Discussion
Our findings demonstrated that preoperative thrombo-
cytosis in patients with resectable NSCLC was signifi-
cantly associated with an increased risk of death andTable 3 Univariate and multivariate analysis of prognostic fac
Variable Category Univa
HR (95% CI)
Age (years) >65/≤64 1.62 (1.04 to 2.52)
Gender Female/Male 1.20 (0.72 to 2.00)
Smoking Yes/No 1.14 (0.71 to 1.81)
Histology Others/ADC 0.84 (0.76 to 1.85)
Stage II + III/I 2.76 (1.72 to 4.41)
pT 2 to 4/1 2.05 (1.05 to 3.98)
pN 1 to 3/0 1.82 (1.17 to 2.81)
Leukocytosis Yes/No 1.17 (0.51 to 2.70)
Anemia Yes/No 1.66 (1.04 to 2.64)
Thrombocytosis Yes/No 2.61 (1.33 to 5.24)
ADC, adenocarcinoma; CI, confidence interval; HR, hazard ratio.disease recurrence. Several previous studies suggested
that anemia or leukocytosis in patients with NSCLC
might have a negative impact on survival [2-4]. However,
our study did not show a relationship between other
preoperative hematologic malignancies, namely anemia
and leukocytosis, and adverse outcomes. In addition, our
study showed that preoperative thrombocytosis was sig-
nificantly associated with smoking history. Previous stud-
ies have shown a positive association between smoking
and elevated platelet count [8-10]. Although the exact me-
chanism by which cigarette smoking induces changes in
platelet counts is unclear, the systemic inflammatory re-
sponse induced by cigarette smoking might contribute to
increased platelet counts [11].
A relationship between elevated platelet counts and
malignant tumors was initially reported by Reiss et al. in
1872 [12]. To date, thrombocytosis has been estimated
to occur in approximately 10% to 57% of cancer patients
with different solid tumors [13]. In our study, 7.5% of
patients with resectable NSCLC had thrombocytosis. The
incidence of thrombocytosis in our study was lower than
that in previous reports. This may be because we excluded
patients with unresectable or metastatic lung cancer from
our study.
Correlations between thrombocytosis and shorter sur-
vival times have been shown for many solid tumors
including gynecological cancers [14-16], gastric cancer
[17,18], esophageal cancer [19], rectal cancer [20,21], and
lung cancer [3,6,22]. Recently, Kawai et al. [21] suggested
that the preoperative platelet count before chemoradio-
therapy can be a potential predictive marker of response
to treatment and of risk of local recurrence after treat-
ment in rectal cancer patients. They hypothesized that
platelets may play a pivotal role in the regulation of radio-
resistance in colorectal cancer. However, a few studies
evaluate the relationship between the prognosis of cancer
patients and the post-treatment platelet count. Lee et al.tors for disease-free survival
riate Multivariate
P value HR (95% CI) P value









0.007 2.47 (1.22-5.01) 0.012
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motherapy in patients with advanced epithelial ovarian
cancer was an independent prognostic factor. In our
study, three patients showed persistent thrombocyto-
sis after surgical resection. They had poorer outcomes
than did patients in whom platelet levels recovered to
normal after surgery.
The mechanism underlying thrombocytosis in cancer
patients is not yet fully understood. It is also unclear
whether thrombocytosis is a reaction to more aggressive
tumors or an active disorder that aggravates cancer
progression. Nevertheless, several mechanisms of both
tumor-induced platelet activation and platelet-induced
cancer progression have been reported. Tumor-related
humoral factors, such as granulocyte colony-stimulating
factor, interleukin-1, and interleukin-6, may play a role in
stimulating megakaryocyte growth and platelet production
[24-26]. In addition, recent experimental studies using
in vitro and in vivo murine models have demonstrated
that platelets activated by cancer cells may induce the ad-
hesion, growth, and distant metastasis. Platelets provide a
procoagulant surface to facilitate cancer-related coagula-
tion; thus, platelet adhesion to the tumor cells may protect
the tumor cells from immune responses that will lead
to cancer growth and dissemination [27]. Although there
is increasing evidence that platelets contribute to tumor
progression and metastasis, the molecular mechanisms
through which platelets worsen prognosis of cancer pa-
tients still need to be studied.
Our study had the limitations of retrospective study, in-
cluding the relatively small number of patients from a sin-
gle hospital. Because of the limited number of patients,
our results should be interpreted cautiously. In addition,
the impact of preoperative and postoperative treatment-
related outcome was not evaluated in this study.
Conclusions
In conclusion, preoperative thrombocytosis is an inde-
pendent poor prognostic marker for resectable NSCLC.
Additionally, our data showed that persistent thrombo-
cytosis may also be a predictive marker for recurrence.
Further prospective studies with a larger sample size are
required to confirm the prognostic value of preoperative
and persistent thrombocytosis in NSCLC patients.
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